Arrowhead Pharmaceuticals Inc. has released a corporate presentation highlighting its recent achievements and future plans. The company reported its first commercial launch in 2025 with REDEMPLO® (plozasiran), an RNAi therapeutic. Arrowhead's TRiM™ platform enables delivery of RNAi therapies to seven different cell types, supporting a robust pipeline that includes wholly owned and partnered candidates targeting conditions in the liver, lung, skeletal muscle, CNS, adipose tissue, ocular tissue, and cardiomyocytes. As of December 2025, Arrowhead's market capitalization stands at approximately $7.65 billion, with cash and investments totaling $920 million, not including additional milestone and upfront payments. Ongoing Phase 3 studies for plozasiran in severe hypertriglyceridemia are expected to deliver results in the third quarter of 2026. The company is also advancing ARO-DIMER-PA targeting PCSK9 and APOC3, with a first clinical readout anticipated in the second half of 2026. Arrowhead reports being financially positioned to fund operations into 2028. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.
Comments